{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:09:11Z","timestamp":1759813751448,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.arteri.2021.09.004","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T08:52:30Z","timestamp":1638780750000},"page":"57-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["El \u00e1cido bempedoico como activador PPAR\u03b1: Nuevas perspectivas para el tratamiento de la esteatosis hep\u00e1tica en un modelo experimental de rata hembra"],"prefix":"10.1016","volume":"34","author":[{"given":"Roger","family":"Bentanachs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Magdalena","family":"Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Mar\u00eda","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Alegret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Laguna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Roglans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2021.09.004_bib0180","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.arteri.2021.09.004_bib0185","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijcard.2015.08.107","article-title":"Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders","volume":"201","author":"Lim","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.arteri.2021.09.004_bib0190","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.3390\/ijms20081948","article-title":"Pathophysiological, molecular and therapeutic issues of nonalcoholic fatty liver disease: An overview","volume":"20","author":"Marchisello","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arteri.2021.09.004_bib0195","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.arteri.2021.09.004_bib0200","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1073\/pnas.0914798107","article-title":"Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis","volume":"107","author":"Li","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.arteri.2021.09.004_bib0205","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.23861","article-title":"Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity","volume":"52","author":"Sachithanandan","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.arteri.2021.09.004_bib0210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00004836-200308000-00017","article-title":"Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis","volume":"37","author":"Koruk","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.arteri.2021.09.004_bib0215","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00125-005-0125-z","article-title":"Overproduction of large VLDL particles is driven by increased liver fat content in man","volume":"49","author":"Adiels","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.arteri.2021.09.004_bib0220","first-page":"20","article-title":"Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications","volume":"11","author":"Andronescu","year":"2018","journal-title":"J Med Life"},{"key":"10.1016\/j.arteri.2021.09.004_bib0225","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Current Atherosclerosis Reports"},{"key":"10.1016\/j.arteri.2021.09.004_bib0230","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/13543784.2020.1668375","article-title":"Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Westerouen van Meeteren","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.arteri.2021.09.004_bib0235","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","article-title":"GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.arteri.2021.09.004_bib0240","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.molmed.2017.09.001","article-title":"Targeting ATP-citrate lyase in hyperlipidemia and metabolic disorders","volume":"23","author":"Pinkosky","year":"2017","journal-title":"Trends Mol Med."},{"key":"10.1016\/j.arteri.2021.09.004_bib0245","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2021.09.004_bib0250","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/13543784.2020.1778668","article-title":"Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential","volume":"29","author":"Brandts","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.arteri.2021.09.004_bib0255","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2021.09.004_bib0260","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/ATVBAHA.116.308963","article-title":"Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr-\/- mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid","volume":"37","author":"Samsoondar","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.1016\/j.arteri.2021.09.004_bib0265","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbalip.2014.11.003","article-title":"Fructose supplementation impairs rat liver autophagy through mTORC activation without inducing endoplasmic reticulum stress","volume":"1851","author":"Baena","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.arteri.2021.09.004_bib0270","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3390\/ijms20051117","article-title":"mTOR is a key protein involved in the metabolic effects of simple sugars","volume":"20","author":"Sang\u00fcesa","year":"2019","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.arteri.2021.09.004_bib0275","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1006\/jfca.2000.0984","article-title":"Composition of genuine cocoa butter and cocoa butter equivalents","volume":"14","author":"Lipp","year":"2001","journal-title":"J Food Compos Anal."},{"key":"10.1016\/j.arteri.2021.09.004_bib0280","doi-asserted-by":"crossref","first-page":"E421","DOI":"10.1152\/ajpendo.00157.2006","article-title":"PPAR\u03b1 mediates the hypolipidemic action of fibrates by antagonizing FoxO1","volume":"292","author":"Qu","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.arteri.2021.09.004_bib0285","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jnutbio.2016.10.015","article-title":"Liquid fructose in Western-diet-fed mice impairs liver insulin signaling and causes cholesterol and triglyceride loading without changing calorie intake and body weight","volume":"40","author":"Baena","year":"2017","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.arteri.2021.09.004_bib0290","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/hep.21499","article-title":"Impairment of hepatic STAT-3 activation and reduction of PPAR\u03b1 activity in fructose-fed rats","volume":"45","author":"Roglans","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.arteri.2021.09.004_bib0295","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1016\/j.arteri.2021.09.004_bib0300","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.arteri.2021.09.004_bib0305","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/hep.22523","article-title":"Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of serine\/threonine (Ser\/Thr) phosphoproteins involved in leptin transduction mediate the effect of Fructose on rat liver lipid metabolism","volume":"48","author":"Vil\u00e0","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.arteri.2021.09.004_bib0310","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.plipres.2012.08.002","article-title":"Stearoyl-CoA desaturase: Rogue or innocent bystander?","volume":"52","author":"Hodson","year":"2013","journal-title":"Prog Lipid Res."},{"key":"10.1016\/j.arteri.2021.09.004_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12113240","article-title":"Effects of a low dose of caffeine alone or as part of a green coffee extract, in a rat dietary model of lean non-alcoholic fatty liver disease without inflammation","volume":"12","author":"Vel\u00e1zquez","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.arteri.2021.09.004_bib0320","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.arteri.2021.09.004_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JIR.S229691","article-title":"Saturated fatty acids in obesity-associated inflammation","volume":"13","author":"Zhou","year":"2020","journal-title":"J Inflamm Res."},{"key":"10.1016\/j.arteri.2021.09.004_bib0330","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1210\/en.2014-1454","article-title":"Restoration of autophagy alleviates hepatic ER stress and impaired insulin signalling transduction in high fructose-fed male mice","volume":"156","author":"Wang","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.arteri.2021.09.004_bib0335","doi-asserted-by":"crossref","first-page":"11107","DOI":"10.1074\/jbc.M708700200","article-title":"Oleate reverses palmitate-induced insulin resistance and inflammation in skeletal muscle cells","volume":"283","author":"Coll","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.arteri.2021.09.004_bib0340","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s00109-005-0678-9","article-title":"Peroxisome proliferator-activated receptor-\u03b1 and liver cancer: Where do we stand?","volume":"83","author":"Peters","year":"2005","journal-title":"J Mol Med (Berl)."},{"key":"10.1016\/j.arteri.2021.09.004_bib0345","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tox.2007.09.030","article-title":"PPAR\u03b1: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators","volume":"246","author":"Gonzalez","year":"2008","journal-title":"Toxicology"},{"key":"10.1016\/j.arteri.2021.09.004_bib0350","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2217\/fca-2016-0059","article-title":"PPARs: Regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-\u03b1","volume":"13","author":"Han","year":"2017","journal-title":"Future Cardiol"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821001376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821001376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:32:39Z","timestamp":1759325559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916821001376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0214916821001376"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2021.09.004","relation":{},"ISSN":["0214-9168"],"issn-type":[{"type":"print","value":"0214-9168"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"El \u00e1cido bempedoico como activador PPAR\u03b1: Nuevas perspectivas para el tratamiento de la esteatosis hep\u00e1tica en un modelo experimental de rata hembra","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2021.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}